Online Pharmacy, Tramadol, Paxil, antibiotics, amoxicillin, zithromax, Rx Online, pharmaceuticals, DHEA, prescription medications, prescription drugs.

Drugs online research references

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Nov;20(11):853-5.
[Experimental study on inhibitory effect of xiaochaihu decoction on duck hepatitis B virus]

[Article in Chinese]

Liu Z, Xiong M, Zhang H.

Guangzhou University of TCM, Guangzhou (510405).

OBJECTIVE: To verify the therapeutic effect of Xiaochaihu decoction (XCHD) on chronic hepatitis B, and to prove the rationality of the TCM principle "strengthening the body resistance to eliminate pathogenic factors". METHODS: The inhibitory effects on DHBV of various doses of XCHD and its ingredients (grouped into whole recipe, partial recipe and single Bupleurum) were determined and compared, as well as compared with that of the blank control and of antiviral drug, acyclovir (ACV). RESULTS: Inhibitory effect was shown in all the treated groups. The treatment by whole recipe of XCHD with the dose 20 times that of clinical use showed the optimal effect, the difference in comparing with other treated groups was significant, P < 0.05. The effect of whole recipe was better than that of the partial recipe or single Bupleurum, P < 0.05. Moreover, the effect was rather persistent, no rebound phenomena was observed after withdrawal of medication, while in the ACV treated group, though a better effect conld be obeained, however, the DHBV returned to the level of before treatment after cessation of ACV treatment. CONCLUSION: The therapeutic effect of XCHD might be to supplment body resistance and remove the evil pathogen, strengthen or regular immune function, so XCHD is efficient in treating chronic hepatitis B.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11938835&dopt=Abstract

Hum Gene Ther. 2002 May 1;13(7):777-89.
Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.

Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L.

Department of Urology, School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.

The herpes simplex virus (HSV) thymidine kinase gene (tk) forms the basis of a widely used strategy for suicide gene therapy. A library of HSV thymidine kinase enzyme (TK) active site mutants having different affinities for guanosine analog prodrugs was developed. We sought to determine the optimal combination of tk variant and prodrug specifically for prostate cancer gene therapy, using in vitro and in vivo studies of adenovirally infected CL1, DU-145, and LNCaP tumor lines carrying wild-type tk, tk30, tk75, and sr39tk mutants expressed by a strong, constitutive cytomegalovirus promoter and treated with ganciclovir and acyclovir. In vitro experiments involving prostate cancer (CaP) cell line infection were carried out with a broad range of prodrug concentrations, and cell killing was determined by limiting dilution (colony-forming), MTT, and propidium iodide assays. In vivo studies based on CL1-GFP xenograft experiments were carried out to examine the ability of each TK variant to prevent tumor formation and to inhibit tumor growth and development of metastases in established orthotopic and subcutaneous tumors in SCID mice. Both in vitro and in vivo studies suggest improved killing with the sr39tk variant. Thus, the results suggest that the use of sr39tk in future trials of prostate cancer tk suicide gene therapy may be beneficial.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11975845&dopt=Abstract

medicine.wisc.edu

New antiviral agents and practice guidelines have been implemented to address cytomegalovirus (CMV) infection in organ transplantation. We hypothesized that such measures would reduce rates of symptomatic CMV infection, CMV disease, and CMV seroconversion and associated complications in renal transplant and simultaneous pancreas-kidney transplant recipients. We analyzed the impact of CMV in 1,424 renal transplant and simultaneous pancreas-kidney transplant recipients, transplanted at our center between January 1, 1994 and June 30, 1999. Most patients received quadruple sequential immunosuppression with high-dose acyclovir (800 mg four times daily) for 12 weeks as prophylaxis. High-risk patients (donor CMV-positive/recipient CMV-negative) received ganciclovir (500 to 1,000 mg three times daily) beginning in 1998, again for 12 weeks. One hundred and one renal transplant (9.0%) and 40 simultaneous pancreas-kidney transplant (13.4%) recipients experienced symptomatic CMV infection or CMV disease. Donor CMV-positive/recipient CMV-negative patients had the greatest rates of CMV infection or CMV disease (25.2%; P = 0.0001 versus all other categories). The impact of CMV on outcomes was evaluated in a proportional hazards model. Symptomatic CMV infection or CMV disease increased the risk for subsequent rejection (relative risk, 2.11; P = 0.003) and non-CMV infection (relative risk, 2.24; P = 0.001). To determine if the effects of ganciclovir were masked by pre-1998 data, CMV infection and CMV disease rates for ganciclovir-treated patients (n = 62) were censored at 1 year and compared with acyclovir-treated patients (n = 287). Ganciclovir was associated with trends toward lower rates of infection and disease. It also delayed the time to infection or disease. Serologic testing in high-risk patients also showed late seroconversion, with 20% of patients seroconverting by 6 months, 12 weeks after the prophylaxis period. These data suggest that despite better prophylaxis strategies, CMV remains an important pathogen in renal transplant and simultaneous pancreas-kidney transplant recipients. This finding may require reassessment of prophylaxis strategies and the development of alternative or novel anti-CMV regimens. Copyright 2002 by the National Kidney Foundation, Inc.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11979354&dopt=Abstract

online pharmacies || Hair Million herbal formula for hair loss and hair growth || Tramadol || Antibiotics and prescription medications online literature || Antibiotics